{"entity":{"id":"nct06506643","kind":"trial","name":"Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms","aka":[],"tldr":"A phase 1/2 trial of Zinc-64 Aspartate in advanced solid tumours, run by Vector Vitale LLC, now recruiting.","summary":"Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms is a phase 1/2 interventional study registered as NCT06506643 by Vector Vitale LLC, with 36 participants planned, started 2024-05-15 and due to reach its primary completion in 2028-12-31. Interventions recorded: Zinc-64 Aspartate.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06506643","url":"https://clinicaltrials.gov/study/NCT06506643"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06506643","phase":"1/2","setting":"A Phase I/II Open-label Multicenter Dose Escalation and Dose Expansion Study to Evaluate the Safety and Efficacy of KLS-1 as Monotherapy in Patients With Malignant Neoplasms","sponsor":"Vector Vitale LLC","enrolled":36,"outcomes":[]},"route":"/trials/nct06506643/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}